Lysine

Lysine

SCHEMBL16893975

Cl.Cl.Cl.NCCCCC(N)C(=O)O

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 2/20 0.95
ARG2 P78540 4/20 0.61
ARG1 P05089 3/20 0.57
RNPEP Q9H4A4 1/20 0.56
NOS2 P35228 4/20 0.53
NOS1 P29475 3/20 0.53
BLM P54132 1/20 0.53
CYP1A2 P05177 3/20 0.50
NOS3 P29474 2/20 0.50
GGT1 P19440 2/20 0.50
TSHR P16473 2/20 0.50
CYP3A4 P08684 1/20 0.50
GRM8 O00222 1/20 0.50
GRM6 O15303 1/20 0.50
GRIN2D O15399 1/20 0.50
GRIN3B O60391 1/20 0.50
GRIK1 P39086 1/20 0.50
GRM5 P41594 1/20 0.50
GRIA1 P42261 1/20 0.50
GRIA2 P42262 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lysine SCHEMBL875015 1.00 GSR (0.95) GSRARG2ARG1RNPEPNOS2
Lysine SCHEMBL706905 1.00 GSR (0.95) GSRARG2ARG1RNPEPNOS2
Lysine SCHEMBL8029574 1.00 GSR (0.95) GSRARG2ARG1RNPEPNOS2
Lysine SCHEMBL41761 1.00 GSR (0.95) GSRARG2ARG1RNPEPNOS2
Lysine SCHEMBL1191963 1.00 GSR (0.95) GSRARG2ARG1RNPEPNOS2
Lysine SCHEMBL10582149 1.00 GSR (0.95) GSRARG2ARG1RNPEPNOS2
Lysine SCHEMBL9762590 1.00 GSR (0.95) GSRARG2ARG1RNPEPNOS2
Lysine SCHEMBL41760 1.00 GSR (0.95) GSRARG2ARG1RNPEPNOS2
Lysine SCHEMBL2478576 1.00 GSR (0.95) GSRARG2ARG1RNPEPNOS2
Lysine SCHEMBL30928253 1.00 GSR (0.95) GSRARG2ARG1RNPEPNOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011344-A1 PRODRUGS AND DERIVATIVES OF PSILOCIN AND USES THEREOF TERRAN BIOSCIENCES INC (US) 2025-01-09 US disclosed
US-20240335592-A1 NANOCRYSTALLINE HYDROXYAPATITE/POLYURETHANE HYBRID POLYMERS AND SYNTHESIS THEREOF VANDERBILT UNIVERSITY 2024-10-10 US disclosed
EP-4387608-A1 PRODRUGS AND DERIVATIVES OF PSILOCIN AND USES THEREOF Terran Biosciences, Inc. (US) 2024-06-26 EP disclosed
CN-118119389-A Prodrugs and derivatives of des-phosphate nupharicin and uses thereof 人类生物科学股份有限公司 2024-05-31 CN disclosed
CN-117956991-A N, N-dimethyltryptamine and related hallucinogens and uses thereof 人类生物科学股份有限公司 2024-04-30 CN disclosed
US-11866408-B2 N,N-dimethyltryptamine and related psychedelics and uses thereof TERRAN BIOSCIENCES INC. (US) 2024-01-09 US disclosed
US-20230212119-A1 N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF TERRAN BIOSCIENCES INC. 2023-07-06 US disclosed
WO-2023023347-A1 PRODRUGS AND DERIVATIVES OF PSILOCIN AND USES THEREOF TERRAN BIOSCIENCES INC. (US) 2023-02-23 WO disclosed
US-20220409772-A1 NANOCRYSTALLINE HYDROXYAPATITE/POLYURETHANE HYBRID POLYMERS AND SYNTHESIS THEREOF VANDERBILT UNIVERSITY 2022-12-29 US disclosed
US-20180311413-A1 NANOCRYSTALLINE HYDROXYAPATITE/POLYURETHANE HYBRID POLYMERS AND SYNTHESIS THEREOF VANDERBILT UNIVERSITY 2018-11-01 US disclosed
EP-3362572-A1 NANOCRYSTALLINE HYDROXYAPATITE/POLYURETHANE HYBRID POLYMERS AND SYNTHESIS THEREOF Vanderbilt University (US) 2018-08-22 EP disclosed
US-20170121278-A1 METHODS AND COMPOSITIONS FOR MAKING AN AMINO ACID TRIISOCYANATE WARSAW ORTHOPEDIC INC (US) 2017-05-04 US disclosed
WO-2017066807-A1 NANOCRYSTALLINE HYDROXYAPATITE/POLYURETHANE HYBRID POLYMERS AND SYNTHESIS THEREOF VANDERBILT UNIVERSITY (US) 2017-04-20 WO disclosed
US-9573889-B2 Methods and compositions for making an amino acid triisocyanate WARSAW ORTHOPEDIC, INC. (US) 2017-02-21 US disclosed
US-20160168085-A1 METHODS AND COMPOSITIONS FOR MAKING AN AMINO ACID TRIISOCYANATE WARSAW ORTHOPEDIC INC (US) 2016-06-16 US disclosed
US-9266824-B2 Methods and compositions for making an amino acid triisocyanate WARSAW ORTHOPEDIC, INC. (US) 2016-02-23 US disclosed
US-20150197483-A1 METHODS AND COMPOSITIONS FOR MAKING AN AMINO ACID TRIHYDROCHLORIDE WARSAW ORTHOPEDIC, INC. (US) 2015-07-16 US disclosed
US-20150197488-A1 METHODS AND COMPOSITIONS FOR MAKING AN AMINO ACID TRIISOCYANATE WARSAW ORTHOPEDIC, INC. (US) 2015-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121278-A1 METHODS AND COMPOSITIONS FOR MAKING AN AMINO ACID TRIISOCYANATE AADAT, AGT, PHYKPL GSR 3482/4885ARG2 1485/4885ARG1 571/4885
US-20150197483-A1 METHODS AND COMPOSITIONS FOR MAKING AN AMINO ACID TRIHYDROCHLORIDE ALKBH3, AADAT, ALKBH1 GSR 4740/4885ARG2 198/4885ARG1 87/4885
US-20150197488-A1 METHODS AND COMPOSITIONS FOR MAKING AN AMINO ACID TRIISOCYANATE AADAT, AGT, PHYKPL GSR 3482/4885ARG2 1485/4885ARG1 571/4885
US-20230212119-A1 N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF PNMT, HTR5A, HNMT GSR 2549/4885ARG2 3127/4885ARG1 3446/4885
US-20160168085-A1 METHODS AND COMPOSITIONS FOR MAKING AN AMINO ACID TRIISOCYANATE AADAT, AGT, PHYKPL GSR 3482/4885ARG2 1485/4885ARG1 571/4885
US-20250011344-A1 PRODRUGS AND DERIVATIVES OF PSILOCIN AND USES THEREOF PSAP, PIGO, PSAT1 GSR 288/4885ARG2 3013/4885ARG1 4591/4885
US-11866408-B2 N,N-dimethyltryptamine and related psychedelics and uses thereof PNMT, HTR5A, HNMT GSR 2549/4885ARG2 3127/4885ARG1 3446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.